Indian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...

Uzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbe...

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

Has a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...

If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

The U.S. Supreme Court is reviewing significant cases. These cases cover voting rights, presidential authority, immigration policies, and g...

The Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to aff...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Gilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. Th...

Pfizer and 3SBio Inc. have entered into a licensing agreement valued at approximately $6 billion for the development, manufacturing, and co...

The city-based pharma company is expected to file the New Drug Application (NDA)with US Food and Drug Administration with regard the migrai...

It may be too early to forecast how Glenmark’s drugs will fare, for the next few years, the generics business will continue to be key.

UACT is an international network of people affected by cancer who share the conviction that cancer treatment and care should be available e...

A superior option is for the government to impose price controls on expensive drugs, whether imported or produced domestically.

Intellectual Property Appellate Board of Chennai dismissed Bayer's plea, seeking a stay on Compulsory License issued to Natco to make Nexav...

Healthcare groups, campaigning for access to medicines, are going all out in their fight against drug patents in India.